Fincom Investment Partners
Special situations

Bohai Pharmaceuticals: Selling Below 2 X Earnings. A Real Bargain In A Hot Market

Bohai Pharmaceuticals Group (OTCQB:BOPH) is a Gold Medal manufacturer of medicines in China. Founded in 2004, Bohai fits with the modern, growing China; a more affluent middle class, while maintaining deep roots in a medical tradition lasting 2000 years.

Corporate headquarters

(click to enlarge)

Photo sources: Bohai

The numbers are eye-popping

Since their 2010 U.S. listing, Bohai's revenues have grown from $59 mm to $178 mm (per issued guidance for fiscal 2014)(June 30th) and FY earnings are expected to leap to $1.22 per share. Thus in 2 months Bohai will be selling below 2X trailing earnings. Current (tangible) Book Value is $5.60, which places Bohai clearly (our vote, at least) as "the world's most undervalued stock".

In a

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details